291 related articles for article (PubMed ID: 2834842)
1. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
2. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
Saito H; Sato K; Tomioka H
Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
[No Abstract] [Full Text] [Related]
3. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
Heifets LB; Lindholm-Levy PJ; Flory MA
Am Rev Respir Dis; 1990 Mar; 141(3):626-30. PubMed ID: 2155555
[TBL] [Abstract][Full Text] [Related]
4. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
Dhillon J; Mitchison DA
Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
[TBL] [Abstract][Full Text] [Related]
5. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
Truffot-Pernot C; Giroir AM; Maury L; Grosset J
Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
Woodley CL; Kilburn JO
Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex.
Saito H; Sato K; Tomioka H
Tubercle; 1988 Sep; 69(3):187-92. PubMed ID: 2855458
[TBL] [Abstract][Full Text] [Related]
8. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):183-93. PubMed ID: 2834843
[TBL] [Abstract][Full Text] [Related]
9. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
10. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.
Rastogi N; Goh KS; Berchel M; Bryskier A
J Antimicrob Chemother; 2000 Oct; 46(4):565-70. PubMed ID: 11020253
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).
Dickinson JM; Mitchison DA
Tubercle; 1990 Jun; 71(2):109-15. PubMed ID: 2120827
[TBL] [Abstract][Full Text] [Related]
12. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis.
Bodmer T; Zürcher G; Imboden P; Telenti A
J Antimicrob Chemother; 1995 Feb; 35(2):345-8. PubMed ID: 7759399
[No Abstract] [Full Text] [Related]
13. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.
Senol G; Erbaycu A; Ozsöz A
J Chemother; 2005 Aug; 17(4):380-4. PubMed ID: 16167516
[TBL] [Abstract][Full Text] [Related]
14. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].
Yamamoto T; Amitani R; Kuze F; Suzuki K
Kekkaku; 1990 Dec; 65(12):805-10. PubMed ID: 2127615
[TBL] [Abstract][Full Text] [Related]
15. Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.
Mosaei H; Molodtsov V; Kepplinger B; Harbottle J; Moon CW; Jeeves RE; Ceccaroni L; Shin Y; Morton-Laing S; Marrs ECL; Wills C; Clegg W; Yuzenkova Y; Perry JD; Bacon J; Errington J; Allenby NEE; Hall MJ; Murakami KS; Zenkin N
Mol Cell; 2018 Oct; 72(2):263-274.e5. PubMed ID: 30244835
[TBL] [Abstract][Full Text] [Related]
16. Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis.
Ungheri D; Della Bruna C; Sanfilippo A
G Ital Chemioter; 1984; 31(3):211-4. PubMed ID: 6100178
[No Abstract] [Full Text] [Related]
17. [Activities of rifabutine and rifampicin against Mycobacterium avium complex infections in mice and in peritoneal macrophages].
Saito H; Sato K; Tomioka H
Kekkaku; 1988 Mar; 63(3):173-9. PubMed ID: 2836650
[No Abstract] [Full Text] [Related]
18. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
Heifets LB; Lindholm-Levy PJ; Iseman MD
Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.
Farhat MR; Sixsmith J; Calderon R; Hicks ND; Fortune SM; Murray M
J Antimicrob Chemother; 2019 Jun; 74(6):1477-1483. PubMed ID: 30793747
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo chemotherapeutic activity of rifabutin (LM 427) on Mycobacterium avium-intracellulare complex.
Sakurai N; Kuze F
Bull Chest Dis Res Inst Kyoto Univ; 1987 Mar; 20(1-2):50-60. PubMed ID: 2836007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
